The impact of COVID-19 on cognition in severe cases highlights the need for comprehensive neuropsychological evaluations in all survivors

Neuropsychopharmacology. 2021 Dec;46(13):2225. doi: 10.1038/s41386-021-00995-7. Epub 2021 Mar 22.

Authors

Katherine E Burdick^{1

2}, Caitlin E Millett^{3

4}

Affiliations

¹ Mood and Psychosis Research Program, Department of Psychiatry, Brigham and Women's Hospital, Boston, MA, USA. kburdick1@bwh.harvard.edu.
² Department of Psychiatry, Harvard Medical School, Boston, MA, USA. kburdick1@bwh.harvard.edu.
³ Mood and Psychosis Research Program, Department of Psychiatry, Brigham and Women's Hospital, Boston, MA, USA.
⁴ Department of Psychiatry, Harvard Medical School, Boston, MA, USA.

No abstract available

Publication types

Comment

MeSH terms

COVID-19*
Cognition
Humans
Neuropsychological Tests
SARS-CoV-2
Survivors